Style Sampler

Layout Style

Patterns for Boxed Mode

Backgrounds for Boxed Mode

All fields are required.

Close Appointment form
slider loading
  • Slider image 0

    Worldwide Leader

    in stem cell therapy with more than 4,000 successful therapies to date
  • Slider image 1

    Research Driven

    testing and documenting each detail
  • Slider image 2

    Worldwide Leader

    in stem cell therapy with more than 4,000 successful therapies to date
  • Slider image 3

    Providing Access

    to quality healthcare to people in need around the world



Blue Horizon International is the world’s leading provider of adult and children’s stem cell therapies. We have safely and efficiently performed more than 4,000 stem cell therapies to date. We are the only treatment provider approved and associated with The Wuhan University Department of Medicine, The Biochemistry Institute of Wuhan University. We are fully licensed by the Ministry of Health of the Slovak Republic to offer cord blood, bone marrow and adipose stem cell derived treatments at Malacky Hospital near Bratislava, Slovakia.



  • Our recent research has been published in “Experimental and therapeutic medicine” cited at PubMed Central, US National Library of Medicine, National Institutes of Health; “CellR4”, the official journal of The Cure Alliance; and presented at the American Academy of Orthopedic Surgeons Annual Meeting (New Orleans, LA, 2018), Adult Stem Cells and Regenerative Medicine Conference, The New York Academy of Sciences (NY, 2019), 7th Annual German Stem Cell Network Conference (Germany, Berlin, 2019). 
  • Our stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice.
  • Our results show our cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions.
  • The Food and Drug Administration (FDA) has given us approval to proceed with our Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke. The study is registered at the ( Identifier: NCT03735277).

Please click on the files below to learn more about our research:

BHI Umbilical Cord Blood

BHI Conditioned Media

BHI Adipose Tissue